Li2016 - Model for pancreatic cancer patients receiving immunotherapy
Model Identifier
BIOMD0000000929
Short description
immunotherapy offers a better prognosis for pancreatic cancer patients. As a direct extension of this work, various new therapy methods that are under exploration and clinical trials could be assessed or evaluated using the newly developed mathematical prognosis model.
Format
SBML
(L2V4)
Related Publication
-
A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy.
- Li X, Xu JX
- Journal of theoretical biology , 10/ 2016 , Volume 406 , pages: 42-51 , PubMed ID: 27338302
- Department of Electrical and Computer Engineering, National University of Singapore, Singapore 117576, Singapore.
- Pancreatic cancer is one of the most deadly types of cancer since it typically spreads rapidly and can seldom be detected in its early stage. Pancreatic cancer therapy is thus a challenging task, and appropriate prognosis or assessment for pancreatic cancer therapy is of critical importance. In this work, based on available clinical data in Niu et al. (2013) we develop a mathematical prognosis model that can predict the overall survival of pancreatic cancer patients who receive immunotherapy. The mathematical model incorporates pancreatic cancer cells, pancreatic stellate cells, three major classes of immune effector cells CD8+ T cells, natural killer cells, helper T cells, and two major classes of cytokines interleukin-2 (IL-2) and interferon-γ (IFN-γ). The proposed model describes the dynamic interaction between tumor and immune cells. In order for the model to be able to generate appropriate prognostic results for disease progression, the distribution and stability properties of equilibria in the mathematical model are computed and analysed in absence of treatments. In addition, numerical simulations for disease progression with or without treatments are performed. It turns out that the median overall survival associated with CIK immunotherapy is prolonged from 7 to 13months compared with the survival without treatment, this is consistent with the clinical data observed in Niu et al. (2013). The validity of the proposed mathematical prognosis model is thus verified. Our study confirms that immunotherapy offers a better prognosis for pancreatic cancer patients. As a direct extension of this work, various new therapy methods that are under exploration and clinical trials could be assessed or evaluated using the newly developed mathematical prognosis model.
Contributors
Submitter of the first revision: Krishna Kumar Tiwari
Submitter of this revision: Krishna Kumar Tiwari
Modellers: Krishna Kumar Tiwari
Submitter of this revision: Krishna Kumar Tiwari
Modellers: Krishna Kumar Tiwari
Metadata information
is (2 statements)
isDescribedBy (1 statement)
hasTaxon (1 statement)
hasProperty (4 statements)
isDescribedBy (1 statement)
hasTaxon (1 statement)
hasProperty (4 statements)
Mathematical Modelling Ontology
Ordinary differential equation model
Human Disease Ontology cancer
NCIt Cancer Immunotherapy
Human Disease Ontology pancreatic cancer
Human Disease Ontology cancer
NCIt Cancer Immunotherapy
Human Disease Ontology pancreatic cancer
Curation status
Curated
Modelling approach(es)
Tags
Connected external resources
SBGN view in Newt Editor
| Name | Description | Size | Actions |
|---|---|---|---|
Model files |
|||
| Li2016.xml | SBML V2.4 file for the model | 110.36 KB | Preview | Download |
Additional files |
|||
| Li2016.cps | COPASI 4.27(built217) file for the model | 166.69 KB | Preview | Download |
| Li2016.sedml | SEDML file for the model | 9.14 KB | Preview | Download |
- Model originally submitted by : Krishna Kumar Tiwari
- Submitted: Apr 6, 2020 6:07:53 PM
- Last Modified: Apr 6, 2020 6:33:47 PM
Revisions
-
Version: 5
- Submitted on: Apr 6, 2020 6:33:47 PM
- Submitted by: Krishna Kumar Tiwari
- With comment: Automatically added model identifier BIOMD0000000929
-
Version: 3
- Submitted on: Apr 6, 2020 6:07:53 PM
- Submitted by: Krishna Kumar Tiwari
- With comment: Automatically added model identifier BIOMD0000000929
(*) You might be seeing discontinuous
revisions as only public revisions are displayed here. Any private revisions
of this model will only be shown to the submitter and their collaborators.
Legends
: Variable used inside SBML models
: Variable used inside SBML models
Species
| Species | Initial Concentration/Amount |
|---|---|
| Pancreatic cancer cells C pancreatic cancer cell |
1.0E9 mmol |
| helper T cells H | 1.8816E9 mmol |
| NK cells N Natural Killer Cell |
3.528E8 mmol |
| CD8 T cells T 0004219 |
7.0E8 mmol |
Reactions
| Reactions | Rate | Parameters |
|---|---|---|
| Pancreatic_cancer_cells__C => ; NK_cells__N | Pancreas*c_c*NK_cells__N*Pancreatic_cancer_cells__C | c_c = 1.5E-11 |
| helper_T_cells__H => | Pancreas*c_h*helper_T_cells__H^2 | c_h = 5.0E-11 |
| => helper_T_cells__H | Pancreas*a_h | a_h = 9600.0 |
| Pancreatic_cancer_cells__C => ; CD8__T_cells__T | Pancreas*d_c*(CD8__T_cells__T/Pancreatic_cancer_cells__C)^l/(s+(CD8__T_cells__T/Pancreatic_cancer_cells__C)^l)*Pancreatic_cancer_cells__C | l = 0.666666666666667; s = 0.3; d_c = 0.005 |
| => helper_T_cells__H; helper_T_cells__H | Pancreas*p_h*helper_T_cells__H*helper_T_cells__H/(g_h*tau1_alpha1+helper_T_cells__H) | g_h = 0.3; tau1_alpha1 = 2.2483E11; p_h = 0.125 |
| => NK_cells__N | Pancreas*a_n | a_n = 130000.0 |
| => CD8__T_cells__T; helper_T_cells__H | Pancreas*p_t*helper_T_cells__H*CD8__T_cells__T/(g_t*tau1_alpha1+helper_T_cells__H) | p_t = 0.125; tau1_alpha1 = 2.2483E11; g_t = 0.3 |
| NK_cells__N => ; Pancreatic_cancer_cells__C | Pancreas*c_n*Pancreatic_cancer_cells__C*NK_cells__N | c_n = 1.0E-13 |
| => Pancreatic_cancer_cells__C; Pancreatic_stellate_cells__P | Pancreas*mu_c*Pancreatic_stellate_cells__P*Pancreatic_cancer_cells__C*(1-b_c*Pancreatic_cancer_cells__C) | mu_c = 3.482115E-12; b_c = 1.02E-11 |
| => NK_cells__N; CD8__T_cells__T, NK_cells__N, helper_T_cells__H | Pancreas*f_n*(alpha2_tau2*CD8__T_cells__T+beta2_tau2*NK_cells__N+gamma2_tau2*helper_T_cells__H)*NK_cells__N/(h_n+alpha2_tau2*CD8__T_cells__T+beta2_tau2*NK_cells__N+gamma2_tau2*helper_T_cells__H) | beta2_tau2 = 4.4691E-13; gamma2_tau2 = 4.4691E-13; f_n = 0.125; h_n = 0.3; alpha2_tau2 = 4.4691E-13 |
Curator's comment:
(added: 06 Apr 2020, 18:07:31, updated: 06 Apr 2020, 18:07:31)
(added: 06 Apr 2020, 18:07:31, updated: 06 Apr 2020, 18:07:31)
Model created in COPASI 4.24(Built417) and plot generated by Simulating the model for 1000 days with the time interval of 1. Figure depicts the response as per Figure 2 of the literature.